Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

NCT02179658 - Fdaxomicin vs Vancomycin & Clostridioides difficile infection (CDI) (initial)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Study overview:

NCT02179658 - Fdaxomicin vs Vancomycin & Clostridioides difficile infection (CDI) (initial) is a randomized clinical phase III, vancomycin-controlled, double-blind, parallel-group treatment trial studying ﬁdaxomicin (200 mg twice daily, orally) vs vancomycin (125 mg four-times daily, orally) for 10 days in 212 randomized adults with Clostridioides difficile infection (CDI) (initial) (1)

Primary outcome measures:

Global cure rate of CDI (proportion of patients cured at end of treatment with no recurrence during 28-day follow-up). Non-inferiority margin of 10% was pre-speciﬁed.

Results:

Global Cure Rates were

Fi…

References (Sources)

Efﬁcacy and safety of ﬁdaxomicin for the treatment of Clostridioides (Clostridium) difﬁcile infection in a randomized, double-blind, comparative phase III study in Japan
Mikamo et al. 2018 J Infect Chemother 24: 744-52

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!